This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Liver cancer	Enhancer of zeste homolog 2 (EZH2)	<p><i>In vitro</i> and patient tissue studies suggest that inhibiting EZH2 could help treat hepatocellular carcinoma (HCC). In human HCC cells, small interfering RNA against EZH2 decreased proliferation compared with control siRNA. In 179 human HCC tumors, one-third of tumor samples overexpressed EZH2, which was associated with increased tumor progression. Next steps could include testing the effects of EZH2 inhibition <i>in vivo</i>.</p> <p>Epizyme Inc. and Eisai Co. Ltd. have an EZH2 inhibitor in preclinical testing to treat breast cancer and non-Hodgkin's lymphoma (NHL).</p> <p>SciBX 4(19); doi:10.1038/scibx.2011.538 Published online May 12, 2011</p>	Patent and licensing status unavailable	<p>Cheng, A.S.L. <i>et al. Cancer Res.</i>; published online April 21, 2011; doi:10.1158/0008-5472.CAN-10-3342</p> <p>Contact: Alfred S.L. Cheng, The Chinese University of Hong Kong, Hong Kong, China e-mail: alfredcheng@cuhk.edu.hk</p>